SBIR/STTR Research Award

Prevention of Pseudomonas Infection with anti-PcrV

Award identifier 03a3ba8dbeae3176ac11bd9ade5e95a128bf4abdbded3fdde0ad8655cd9d81daAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INTERMUNE PHARMACEUTICALS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): We propose an innovative approach to prevent Pseudomonas aeruginosa infection by blockade of a critical Type III secretory protein with monoclonal antibodies. Pseudomonas causes disease by the release of exotoxins which destroy host tissue and paralyze the phagocytic mechanism of macrophages. To be active, many toxins require translocation from the interior of the bacteria directly into the eukaryotic cell. This translocation (type Ill secretory mechanism) is accomplished by a group of proteins which form a channel from the interior of the bacterium to the interior of the host cell. Preliminary work has shown that one of the type Ill secretory proteins, PcrV, is critical for translocation of toxins into the host cell. Blockade of this protein with active immunization or passive immunization with polyclonal antibodies prevents infection with P. aeruginosa in a murine model of pneumonitis. The overall goal of this Phase I proposal is to develop a murine monoclonal antibody to PcrV to prevent infection with P. aeruginosa. This work should establish proof of principle that a monoclonal antibody to PcrV can prevent infection, thus supporting the development of human monoclonal antibodies as a preventive therapy in patients at high risk for P. aeruginosa infection. PROPOSED COMMERCIAL APPLICATION: Pseudomonas aeruginasa is a major cause of hospital-acquired infection, accounting for 20% of nosocomial pneumonias,10-15% of nosocomial urinary tract infections and 10% of sepsis. In addition, P. aeruginosa infection is the major cause of mortality in cystic fibrosis. Current treatment is associated with a high rate of antibiotic resistance and a 25-50% failure rate. The proposed treatment provides a novel approach to the prevention of P. aervginosa infection in patients at high risk for this infection, including patients on ventilators, bum patients, patients with in-dwelling catheters, neutropenic patients, and patients with cystic fibrosis.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.